Abstract
Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials. See related article by Ahn et al., p. 2039.
©2024 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Cell Cycle Proteins* / antagonists & inhibitors
-
Cell Cycle Proteins* / genetics
-
Colorectal Neoplasms* / drug therapy
-
Colorectal Neoplasms* / genetics
-
Colorectal Neoplasms* / pathology
-
Humans
-
Mutation*
-
Neoplasm Metastasis
-
Polo-Like Kinase 1*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Serine-Threonine Kinases* / antagonists & inhibitors
-
Protein Serine-Threonine Kinases* / genetics
-
Proto-Oncogene Proteins p21(ras)* / genetics
-
Proto-Oncogene Proteins* / antagonists & inhibitors
-
Proto-Oncogene Proteins* / genetics